AxoGen
AXGN
36.04
-0.27
-0.74%
AxoGen
US · AXGN
#2714 by market cap
Listed 1970
36.04
-0.27
-0.74%
Live - 5344 symbols - heartbeat 128s ago
· 2026-10-08 05:20
Pre-market
36.02
-0.06%
After-hours
36.04
0.00%
- Market cap
- 2.11B
- P/E (TTM)i
- -53.79
- P/Bi
- 8.25
- EPSi
- -0.34
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on AXGN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 1.4 percentage points.
Institutional ownership
- Held by institutions
- 99.20% -1.39pp
- Institutions
- 303
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund69.27%
Hedge Fund17.96%
Public Company8.09%
Individual/Insider1.95%
Private Company1.72%
Government Pension Fund1.13%
Insurance Company0.56%
VC/PE Fund0.42%
Top holders as of 2026-06-30
BlackRock
7.53% · 4.42M sh
Divisadero Street Capital Management, LP
6.79% · 3.98M sh
First Light Asset Management, LLC
4.68% · 2.75M sh
Vanguard Capital Management, LLC
4.49% · 2.64M sh
Morgan Stanley
4.49% · 2.64M sh
Polar Capital Holdings Plc
2.56% · 1.50M sh
Artemis Investment Management LLP
2.38% · 1.40M sh
Wellington Management Group
2.37% · 1.39M sh
Geode Capital Management, LLC
2.34% · 1.38M sh
Citadel Advisors LLC
2.32% · 1.36M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 29 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| Erick DeVinney | Vice President of Peripheral Nerve Science and Clinical Innovation | 0.41% |
| Amy McBride-Wendell | Lead Independent Director | 0.18% |
| Doris Quackenbush | Officer | 0.16% |
| Jens Kemp | Chief Marketing Officer | 0.12% |
| Lindsey Hartley | Chief Financial Officer | 0.11% |
| Michael Dale | Chief Executive Officer | 0.11% |
| Alan Levine | Independent Director | 0.09% |
| Marc Began | Executive VP, General Counsel & Chief Compliance Officer | 0.09% |
| Paul Thomas | Independent Director | 0.06% |
| William Burke | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Joseph Tyndall | Independent Director | Automatic Disposition | -3,500 | $49.70 |
| 2026-08-10 | Amy McBride-Wendell | Lead Independent Director | Derivative Exercise and Sale | -13,353 | $14.85–48.42 |
| 2026-08-09 | Marc Began | Executive VP, General Counsel & Chief Compliance Officer | Derivative Exercise and Sale | -67,500 | $8.16–47.35 |
| 2026-08-06 | Kathy Weiler | Director | Automatic Disposition | -14,150 | $45.30 |
| 2026-06-23 | Paul Thomas | Independent Director | Other Derivative Acquisition | +5,579 | -- |
| 2026-06-23 | Amy McBride-Wendell | Lead Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | John Johnson | Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | Kathy Weiler | Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | Alan Levine | Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | William Burke | Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | Joseph Tyndall | Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-18 | Paul Thomas | Independent Director | Derivative Exercise and Retained | +18,867 | -- |
| 2026-06-18 | Amy McBride-Wendell | Lead Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | John Johnson | Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | Kathy Weiler | Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | Alan Levine | Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | William Burke | Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | Joseph Tyndall | Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-05-07 | Amy McBride-Wendell | Lead Independent Director | Derivative Exercise and Sale | -1,647 | $14.85–42.60 |
| 2026-05-06 | John Johnson | Independent Director | Derivative Exercise and Sale | -11,050 | $7.04–43.26 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:20:31 · For reference only, not investment advice and not tailored to your situation.